|
Adult T-Cell Lymphoma/Leukemia
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Importantly, we revealed that HTLV-1 bZIP factor (HBZ) protein which is expressed in all ATL cases physically interacts with NRF-1 and inhibits the DNA-binding ability of NRF-1.
|
28993637 |
2017 |
|
Alzheimer's Disease
|
0.010 |
Biomarker
|
disease |
BEFREE |
The female NRF1 gene network is completely different from male human AD patients.
|
27983596 |
2016 |
|
Amyotrophic Lateral Sclerosis
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
PGC-1β, nuclear respiratory factor-1 (NRF-1) and Mfn1 mRNA as well as cytochrome C oxidase subunit IV (COXIV) mRNA and protein were lower in patients with ALS and ND.
|
22975021 |
2013 |
|
Arteriosclerosis
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
Expression of miR-33a/b was markedly increased in human carotid atherosclerotic plaques compared with normal arteries, and there was a concomitant decrease in mitochondrial regulatory genes PGC-1α, SLC25A25, NRF1, and TFAM, suggesting these genes are associated with advanced atherosclerosis in humans.
|
26002865 |
2015 |
|
ATAXIA, EARLY-ONSET, WITH OCULOMOTOR APRAXIA AND HYPOALBUMINEMIA
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
The bioenergetics defect in AOA1-mutant fibroblasts and APTX-depleted Hela cells is caused by decreased expression of SDHA and genes encoding CoQ biosynthetic enzymes, in association with reductions of APE1, NRF1 and NRF2.
|
25976310 |
2015 |
|
Atherosclerosis
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
Expression of miR-33a/b was markedly increased in human carotid atherosclerotic plaques compared with normal arteries, and there was a concomitant decrease in mitochondrial regulatory genes PGC-1α, SLC25A25, NRF1, and TFAM, suggesting these genes are associated with advanced atherosclerosis in humans.
|
26002865 |
2015 |
|
B-Cell Lymphomas
|
0.010 |
AlteredExpression
|
group |
BEFREE |
Furthermore, overexpression of NRF‑1 increased the expression of B‑cell lymphoma‑2, hypoxia inducible factor‑1α and NRF‑2.
|
30628711 |
2019 |
|
Bowen's Disease
|
0.300 |
Biomarker
|
disease |
CTD_human |
Aberrant cell proliferation by enhanced mitochondrial biogenesis via mtTFA in arsenical skin cancers.
|
21514422 |
2011 |
|
Brain Diseases
|
0.010 |
Biomarker
|
group |
BEFREE |
Estrogenic Endocrine Disrupting Chemicals Influencing NRF1 Regulated Gene Networks in the Development of Complex Human Brain Diseases.
|
27983596 |
2016 |
|
Brain Ischemia
|
0.200 |
Biomarker
|
disease |
RGD |
Rapidly increased neuronal mitochondrial biogenesis after hypoxic-ischemic brain injury.
|
18723421 |
2008 |
|
Breast Carcinoma
|
0.060 |
Biomarker
|
disease |
BEFREE |
The gain of NRF1 and/or treatment with 17β-estradiol (E2) produced heterogeneous breast cancer stem cell (BCSC)-like subsets composed of more than 10 distinct cell sub-populations.
|
30486409 |
2018 |
|
Breast Carcinoma
|
0.060 |
AlteredExpression
|
disease |
BEFREE |
With the Luminal A subtype of breast cancer, higher NRF1 expression is associated with lower survival.
|
29995872 |
2018 |
|
Breast Carcinoma
|
0.060 |
Biomarker
|
disease |
BEFREE |
Our analysis found that motifs bound by ELK1, E2F, NRF1 and NFY are potential regulatory motifs that positively correlate with malignant progression of breast cancer.
|
18823535 |
2008 |
|
Breast Carcinoma
|
0.060 |
Biomarker
|
disease |
BEFREE |
These results suggest that Nrf1 and TFAM are potential biomarkers for the determination of individualized therapy and the prognosis of breast cancer, and molecular targeting of Nrf1 and TFAM is a promising strategy for the sensitization of breast cancer cells to chemotherapeutics.
|
29434836 |
2018 |
|
Breast Carcinoma
|
0.060 |
GeneticVariation
|
disease |
BEFREE |
EglN2 associates with the NRF1-PGC1α complex and controls mitochondrial function in breast cancer.
|
26492917 |
2015 |
|
Breast Carcinoma
|
0.060 |
Biomarker
|
disease |
BEFREE |
Since transcriptional control of NRF1 seems to be dependent on epidermal growth factor receptor signaling, herein, we investigated the role of NRF1 in estrogen receptor/progesterone receptor negative, but human epidermal growth factor receptor 2-positive (ER/PR -ve HER2 +ve) breast cancer.
|
30128822 |
2018 |
|
Bulbo-Spinal Atrophy, X-Linked
|
0.010 |
Biomarker
|
disease |
BEFREE |
A small-molecule Nrf1 and Nrf2 activator mitigates polyglutamine toxicity in spinal and bulbar muscular atrophy.
|
26962150 |
2016 |
|
Carcinogenesis
|
0.040 |
Biomarker
|
phenotype |
BEFREE |
Although ZNF746, also known as Parkin-interacting substrate (PARIS), has been reported to suppress peroxisome proliferator-activated receptor γ coactivator-1α (PGC-1α) and its target gene NRF-1 leading to the neurodegeneration in Parkinson's disease, its function in tumorigenesis has yet to be investigated.
|
24145959 |
2014 |
|
Carcinogenesis
|
0.040 |
Biomarker
|
phenotype |
BEFREE |
Consistent with our observation of NRF1-driven breast tumorigenesis in the experimental model, higher protein levels of NRF1 were also found in human breast cancer tissue specimens.
|
30486409 |
2018 |
|
Carcinogenesis
|
0.040 |
AlteredExpression
|
phenotype |
BEFREE |
Mechanistically, nutritional deficiencies could reduce hypoxia-inducible factor α (HIF-1α) protein expression to increase C-MYC protein level, which in turn increased nuclear respiratory factor 1 (NRF1) and mitochondrial transcription factor A (TFAM) transcription to enhance the activity of OXPHOS, suggesting that metabolic reprogramming by the changes of microenvironment during the carcinogenesis can provide some novel therapeutic clues to traditional cancer treatments.
|
26646563 |
2016 |
|
Carcinogenesis
|
0.040 |
Biomarker
|
phenotype |
BEFREE |
Our findings suggest that Nrf1 may play a role in maintaining genomic integrity, and that Nrf1 dysregulation may induce tumorigenesis.
|
22971132 |
2012 |
|
Carcinoma, Ovarian Epithelial
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
Interindividual variation involving BIO was most strongly associated with EOC risk (empirical P = 0.050), especially for NRF1, MTERF, PPARGC1A, ESRRA, and CAMK2D.
|
21447778 |
2011 |
|
Central neuroblastoma
|
0.050 |
PosttranslationalModification
|
disease |
BEFREE |
In the present study, we focused on the epigenetic effects of TBT and investigated whether TBT decreases NRF-1 expression via epigenetic modifications in SH-SY5Y human neuroblastoma cells.
|
29345269 |
2018 |
|
Central neuroblastoma
|
0.050 |
Biomarker
|
disease |
BEFREE |
Notably, there also exists a proteasomal 'bounce-back' response mediated by Nrf1, insofar as to enhance the drug resistance to proteasomal inhibitors in clinical treatment of neuroblastoma, multiple myeloma and triple-negative breast cancers.
|
30267745 |
2018 |
|
Central neuroblastoma
|
0.050 |
Biomarker
|
disease |
BEFREE |
Overall, we annotated FAM134C, C3orf10, and ENOX1 as NRF-1-regulated genes, which have differential effects on neurite outgrowth in neuroblastoma cells as well as neurons.
|
23939472 |
2013 |